A β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei and its application

The antimicrobial peptide PVQ9 of Litopenaeus vannamei β-actin addresses the problem of poor efficacy of existing antibiotics against foodborne pathogens by disrupting bacterial cell walls and binding to DNA. It achieves highly efficient inhibition and killing of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtectomyces griseus, and can be applied in antimicrobial drugs, feed additives, and food preservatives.

CN116621932BActive Publication Date: 2026-11-10JIMEI UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310490895.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2026-11-10
Estimated Expiration
2043-05-04

AI Technical Summary

Technical Problem

Existing antibiotics are not very effective against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cuttlebacter giardi. With the increasing drug resistance of pathogens, finding alternative chemical drugs to control foodborne pathogen contamination has become a research hotspot.

Method used

We provide PVQ9, an antimicrobial peptide of β-actin from Litopenaeus vannamei, with the amino acid sequence AVFPSIVGRPR. It inhibits bacterial DNA synthesis by disrupting the bacterial cell wall, altering cell membrane permeability, and binding to bacterial genomic DNA.

Benefits of technology

PVQ9 has a significant inhibitory effect on the above-mentioned bacteria and can quickly kill bacteria at low concentrations. It can be used to prepare antibacterial drugs, feed additives and food preservatives, effectively controlling bacterial infection and spoilage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116621932B_ABST
    Figure CN116621932B_ABST
Patent Text Reader

Abstract

This invention discloses a β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei, with the amino acid sequence AVFPSIVGRPR. The molecular weight of the antimicrobial peptide PVQ9 is 1198.7055 Daltons. The antimicrobial peptide PVQ9 of this invention exhibits significant inhibitory effects against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, or Curella giardi, and can be used to prepare drugs, feed additives, or food preservatives for the prevention or inhibition of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, or Curella giardi infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei and its applications. Background Technology

[0002] Staphylococcus aureus is a common foodborne pathogen that produces staphylococcal enterotoxins, causing food poisoning accompanied by symptoms such as vomiting, abdominal cramps, and diarrhea. Bacillus cereus is a common sporoforming bacterium. Because its spores can withstand high temperatures and low humidity, they can easily survive for extended periods in food and produce toxins that cause diarrhea and vomiting. Therefore, Bacillus cereus frequently causes contamination and food poisoning in the food industry. Staphylococcus sciuri is a widely distributed bacterium in nature, which can be isolated from various animals and animal-derived foods. It has been confirmed as a pathogen in both humans and animals. Kurthia gibsonii is a novel opportunistic pathogen in poultry. It is also a specific spoilage bacterium for firm tofu, causing changes in color and texture, producing unpleasant odors, and thus shortening the shelf life of tofu. Foodborne pathogen contamination can occur at any stage of food production and consumption, therefore the control of foodborne pathogens is receiving increasing attention in order to address the health crisis caused by foodborne diseases.

[0003] Currently, antibiotics remain one of the most effective methods for addressing foodborne pathogen contamination. However, with the increasing drug resistance of pathogens, existing antibiotics are no longer sufficient to kill them. Therefore, finding alternatives to chemical drugs has become a major research focus. Antimicrobial peptides (AMPs) are a class of natural, small-molecule bioactive peptides with antibacterial or antifungal activity, also known as host defense peptides, produced by organisms such as bacteria, plants, vertebrates, and invertebrates. They possess characteristics such as good water solubility, low toxicity to higher animals, and good thermal stability, and are considered potential alternatives to antibiotics, showing promising applications in food preservatives and feed additives. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a novel antimicrobial peptide PVQ9 from Litopenaeus vannamei β-actin and its application, thus solving the problems mentioned in the background art. This study discovered a novel antimicrobial peptide PVQ9 through Bacillus subtilis fermentation of shrimp heads, which exhibits strong antibacterial activity against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, or Cucurbita gigantea, and further investigated its antibacterial mechanism.

[0005] One of the technical solutions adopted by this invention to solve its technical problem is to provide a Litopenaeus vannamei β-actin antimicrobial peptide PVQ9. Its amino acid sequence is AVFPSIVGRPR, as shown in SEQ ID NO: 1.

[0006] The antimicrobial peptide has a molecular weight of 1198.7055 Daltons, a positive charge of +2, and a total hydrophobicity of 45%.

[0007] The second technical solution adopted by the present invention to solve its technical problem is: to provide the application of Litopenaeus vannamei β-actin antimicrobial peptide PVQ9 in the preparation of antimicrobial drugs, which are used to inhibit and / or kill one or more of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtilium giardi.

[0008] The third technical solution adopted by the present invention to solve its technical problem is: to provide an antibacterial drug, the effective ingredient of which includes β-actin antimicrobial peptide PVQ9 of Litopenaeus vannamei, wherein the amino acid sequence of the antimicrobial peptide PVQ9 is SEQ ID NO: 1.

[0009] In a preferred embodiment of the present invention, the active ingredient of the antibacterial drug is β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei, and the amino acid sequence of the antimicrobial peptide PVQ9 is SEQ ID NO: 1.

[0010] In a preferred embodiment of the present invention, the antibacterial drug is used to inhibit and / or kill one or more of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cuttlebacter giardi.

[0011] The fourth technical solution adopted by the present invention to solve its technical problem is: to provide a feed additive whose effective ingredient includes β-actin antimicrobial peptide PVQ9 of Litopenaeus vannamei, wherein the amino acid sequence of the antimicrobial peptide PVQ9 is SEQ ID NO: 1.

[0012] In a preferred embodiment of the present invention, the effective component of the feed additive is β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei, and the amino acid sequence of the antimicrobial peptide PVQ9 is SEQ ID NO: 1.

[0013] In a preferred embodiment of the present invention, the feed additive is used to inhibit and / or kill one or more of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cuttlebacterium giardi.

[0014] The fifth technical solution adopted by the present invention to solve its technical problem is: to provide a food preservative, the effective ingredient of which is β-actin antimicrobial peptide PVQ9 of Litopenaeus vannamei, and the amino acid sequence of the antimicrobial peptide PVQ9 is SEQ ID NO: 1.

[0015] In a preferred embodiment of the present invention, the food preservative is used to inhibit and / or kill one or more of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cuttlebacterium giardi.

[0016] The antimicrobial peptides of the present invention can be synthesized using methods known to those skilled in the art, such as solid-phase synthesis, and purified using methods known to those skilled in the art, such as high-performance liquid chromatography.

[0017] Implementing this invention has the following beneficial effects:

[0018] This invention investigates the antibacterial activity of antimicrobial peptide PVQ9 against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cucurbita gigantea. The effects of PVQ9 on bacterial cell walls were observed by detecting changes in alkaline phosphatase activity, and the degree of cell membrane disruption caused by PVQ9 was observed by propidium iodide staining. Genomic DNA was extracted from Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cucurbita gigantea to verify its effect on bacterial DNA. The results show that PVQ9 has a significant inhibitory effect on Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cucurbita gigantea. The antimicrobial peptide PVQ9 of this invention is a cationic antimicrobial peptide that exerts its antibacterial effect by disrupting bacterial cell walls, altering cell membrane permeability, penetrating the cell membrane, and binding to bacterial genomic DNA, thereby inhibiting bacterial DNA synthesis.

[0019] The antimicrobial peptide PVQ9 of this invention can be used to prepare drugs, feed additives or food preservatives for preventing or inhibiting infections caused by Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus or Curtes giardi. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the predictive model structure for the antimicrobial peptide PVQ9.

[0021] Figure 2 This is a control chart showing the determination of the minimum bactericidal concentration (MBC) of the antimicrobial peptide PVQ9 against Staphylococcus aureus.

[0022] The AF antimicrobial peptide PVQ9 concentrations were 0 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, and 31.25 μg / mL, respectively.

[0023] Figure 3 This is a control chart showing the determination of the minimum bactericidal concentration (MBC) of the antimicrobial peptide PVQ9 against Bacillus cereus.

[0024] The AF antimicrobial peptide PVQ9 concentrations were 0 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, and 31.25 μg / mL, respectively.

[0025] Figure 4 This is a control chart showing the determination of the minimum bactericidal concentration (MBC) of the antimicrobial peptide PVQ9 against Staphylococcus aureus.

[0026] The AF antimicrobial peptide PVQ9 concentrations were 0 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, 31.25 μg / mL, and 15.625 μg / mL, respectively.

[0027] Figure 5 This is a control chart showing the minimum bactericidal concentration (MBC) determination of the antimicrobial peptide PVQ9 against Cucurbita gigantea.

[0028] The AF antimicrobial peptide PVQ9 concentrations were 0 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, 31.25 μg / mL, and 15.625 μg / mL, respectively.

[0029] Figure 6 This is a time-kill curve of the antimicrobial peptide PVQ9 against Staphylococcus aureus.

[0030] Figure 7 The time-kill curve of antimicrobial peptide PVQ9 against Bacillus cereus.

[0031] Figure 8 The time-kill curve of antimicrobial peptide PVQ9 against Staphylococcus aureus.

[0032] Figure 9 The time-kill curve of antimicrobial peptide PVQ9 against Kutella gigantea.

[0033] Figure 10 Figure showing the effect of antimicrobial peptide PVQ9 on the cell wall of Staphylococcus aureus (alkaline phosphatase leakage).

[0034] Figure 11 Figure showing the effect of antimicrobial peptide PVQ9 on the cell wall of Bacillus cereus (alkaline phosphatase leakage).

[0035] Figure 12 Figure showing the effect of antimicrobial peptide PVQ9 on the cell wall of Staphylococcus aureus (alkaline phosphatase leakage).

[0036] Figure 13 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell wall of *Cootheca gigantea* (alkaline phosphatase leakage).

[0037] Figure 14Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability of Staphylococcus aureus by propidium iodide staining.

[0038] Figure 15 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability of Bacillus cereus by propidium iodide staining.

[0039] Figure 16 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability of Staphylococcus aureus by propidium iodide staining.

[0040] Figure 17 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability of *Cootheca gigantea* by propidium iodide staining.

[0041] Figure 18 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability (protein leakage) of Staphylococcus aureus.

[0042] Figure 19 Figure showing the effect of antimicrobial peptide PVQ9 on cell membrane permeability (protein leakage) of Bacillus cereus.

[0043] Figure 20 Figure showing the effect of antimicrobial peptide PVQ9 on cell membrane permeability (protein leakage) of Staphylococcus aureus.

[0044] Figure 21 Figure showing the effect of the antimicrobial peptide PVQ9 on the cell membrane permeability (protein leakage) of Cuttlebacterium gibberella.

[0045] Figure 22 This is an electrophoresis image of the binding of the antimicrobial peptide PVQ9 to the genomic DNA of Staphylococcus aureus. Band 7 represents the blank control; bands 1-6 represent PVQ9 to DNA mass ratios of 100 / 1, 50 / 1, 25 / 1, 25 / 2, 25 / 4, and 25 / 8, respectively.

[0046] Figure 23 This is an electrophoresis diagram of the binding of antimicrobial peptide PVQ9 to genomic DNA of Bacillus cereus. Band 7 represents the blank control; bands 1-6 represent PVQ9 to DNA mass ratios of 100 / 1, 50 / 1, 25 / 1, 25 / 2, 25 / 4, and 25 / 8, respectively.

[0047] Figure 24 This is an electrophoresis image of the binding of the antimicrobial peptide PVQ9 to the genomic DNA of Staphylococcus aureus. Band 7 represents the blank control; bands 1-6 represent PVQ9 to DNA mass ratios of 100 / 1, 50 / 1, 25 / 1, 25 / 2, 25 / 4, and 25 / 8, respectively.

[0048] Figure 25This is an electrophoresis image of the binding of the antimicrobial peptide PVQ9 to the genomic DNA of Cuttlebacter giardi. Band 7 represents the blank control; bands 1-6 represent PVQ9 to DNA mass ratios of 100 / 1, 50 / 1, 25 / 1, 25 / 2, 25 / 4, and 25 / 8, respectively.

[0049] Figure 26 The fluorescence spectrum of the antimicrobial peptide PVQ9 competitively binding to Staphylococcus aureus genomic DNA is shown.

[0050] Figure 27 The fluorescence spectrum of the antimicrobial peptide PVQ9 competitively binding to the genomic DNA of Bacillus cereus is shown.

[0051] Figure 28 The fluorescence spectrum of the antimicrobial peptide PVQ9 competitively binding to the genomic DNA of Staphylococcus aureus.

[0052] Figure 29 The fluorescence spectrum of the antimicrobial peptide PVQ9 competitively binding to the genomic DNA of Kutella gigantea.

[0053] Figure 30 Images show tofu stored under different treatment conditions for different times. Blank samples are tofu samples that have been sterilized without any treatment. Bacteria + water samples are tofu samples that have been treated with an equal amount of sterile PBS instead of the antimicrobial peptide PVQ9. 1×MBC and 2×MBC samples have PVQ9 added at concentrations of 31.3 μg / mL and 62.5 μg / mL, respectively. Images A, B, C, and D show tofu stored for 12 h, 24 h, 36 h, and 48 h, respectively.

[0054] Figure 31 The graph shows the total number of *Cootrella gigantea* colonies in tofu during storage. The bacteria + water represents the replacement of the antimicrobial peptide PVQ9 with an equal amount of sterile PBS. The 1×MBC and 2×MBC represent the concentrations of PVQ9 added, which are 31.3 μg / mL and 62.5 μg / mL, respectively.

[0055] Figure 32 The graph shows the soluble amino acid nitrogen content in tofu during storage. Control is the tofu sample that has not been treated after sterilization. Bacteria + water is the tofu sample with an equal amount of sterile PBS instead of antimicrobial peptide PVQ9. 1×MBC and 2×MBC are the concentrations of antimicrobial peptide PVQ9 added, which are 31.3 μg / mL and 62.5 μg / mL, respectively.

[0056] Figure 33 The graph shows the pH changes of tofu during storage. Control represents tofu samples that were sterilized without any treatment. Bacteria + water represents tofu samples where an equal amount of sterile PBS was used to replace the antimicrobial peptide PVQ9. 1×MBC and 2×MBC represent the concentrations of antimicrobial peptide PVQ9 added, which are 31.3 μg / mL and 62.5 μg / mL, respectively. Detailed Implementation

[0057] To better understand the present invention, the present invention will be further described in detail below with reference to the embodiments and accompanying drawings. However, those skilled in the art will understand that the following embodiments are not intended to limit the scope of protection of the present invention, and any changes and variations made on the basis of the present invention are within the scope of protection of the present invention.

[0058] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0059] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0060] Example 1: Screening of β-actin antimicrobial peptide PVQ9 from Litopenaeus vannamei

[0061] First, samples were prepared by fermenting the homogenate of fresh Litopenaeus vannamei heads using Bacillus subtilis. Fresh Litopenaeus vannamei head homogenate was liquid-state fermented at 37℃ and 160 rpm using Bacillus subtilis as the starter culture. After fermentation, the supernatant was collected after centrifugation at 3000 rpm for 5 min and filtered through a 3000 Da filter membrane. The sample was then stored at -20℃ for further analysis.

[0062] Chromatographic conditions: Injection volume: 5.0 μL

[0063] Chromatographic column: C18 analytical column, 25cm in length, 75μm in inner diameter.

[0064] Mobile phase: A: 0.1% methanol aqueous solution; B: acetonitrile

[0065] Using the MAXQUANT v1.6.5.0 search software and the uniprot shrimp protein library, the obtained peptide mass spectra were differentiated and identified, yielding 325 peptides. The sequences were then screened using the APD3 online server, and the peptide structure was predicted using the Swiss-model server. It was found to be an antimicrobial peptide with strong antibacterial activity against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curvatella giardi, with the sequence AVFPSIVGRPR, named PVQ9, and a molecular weight of 1198.7055 Daltons.

[0066] Example 2: 3D structure prediction of antimicrobial peptide PVQ9

[0067] The structure of the antimicrobial peptide PVQ9 was predicted using the online structure prediction server Swiss-model, and then edited and modified using Pymol software to obtain the secondary structure of the antimicrobial peptide PVQ9, such as... Figure 1 As shown.

[0068] Example 3: Determination of the minimum bactericidal concentration (MBC) of antimicrobial peptide PVQ9

[0069] Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella giardi were cultured at 37°C to the logarithmic growth phase and then diluted to a final concentration of 10 μL in 0.01 M pH 7.2 phosphate buffer. 5-6 CFU / mL. The antimicrobial peptide PVQ9 was dissolved in phosphate buffer and incubated with an equal volume of bacteria at 37°C for 2 hours. The minimum bactericidal concentration (MBC) refers to the concentration of the antimicrobial peptide that can kill bacteria after incubation at 37°C. For example... Figures 2-5 As shown, the minimum bactericidal concentrations (MBCs) of the antimicrobial peptide PVQ9 against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella giardi were 62.5 μg / mL, 62.5 μg / mL, 31.25 μg / mL, and 31.25 μg / mL, respectively.

[0070] Example 4: Determination of the time-kill curve of antimicrobial peptide PVQ9

[0071] The time-bacterial killing curve of the antimicrobial peptide PVQ9 was determined using the plate count method. Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella giardi were cultured at 37°C to the logarithmic growth phase and then diluted to 10⁻¹⁰ in 0.01M pH 7.2 phosphate buffer. 5-6 CFU / mL. 1×MBC and 2×MBC peptides were mixed with equal volumes of bacterial suspension and incubated at 37°C in a biochemical incubator. At different time points (0.5, 1, 1.5, 2, 2.5, and 3 hours), 0.02 mL of bacterial suspension was obtained and incubated on nutrient broth plates at 37°C for 24 hours before colony counting. Results are as follows: Figures 6-9 As shown, the antimicrobial peptide PVQ9 can kill Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella gibrini within two hours.

[0072] Example 5: Effects of antimicrobial peptide PVQ9 on bacterial cell walls

[0073] Alkaline phosphatase leakage: Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella gibrini were cultured at 37°C to the logarithmic growth phase. A certain amount of bacterial suspension was taken and the collected bacterial cells were washed three times with 0.01M pH 7.2 phosphate buffer, and the bacterial suspension concentration was adjusted to 10. 8CFU / mL. Mix with an equal volume of antimicrobial peptide PVQ9 to final concentrations of 2×MBC and 1×MBC, respectively. Use an equal volume of phosphate buffer and bacterial suspension as a blank control. Incubate at 37℃ for 2 hours, then remove the bacterial suspension and centrifuge at 3500 rpm for 10 minutes to obtain the supernatant. According to the alkaline phosphatase (AKP) kit instructions, at OD... 510 Under certain conditions, the AKP enzyme activity in each supernatant was measured using a 96-well plate and a microplate reader. The changes in AKP enzyme activity were used to reflect the effect of the peptide on the bacterial cell wall. Alkaline phosphatase (AKP) is an intracellular enzyme located between the cell wall and the cell membrane. When the cell wall is damaged, it leaks out of the bacteria and enters the extracellular environment. Therefore, the extent of damage to the bacterial cell wall by antimicrobial peptides can be determined by detecting AKP enzyme activity. Results are as follows... Figures 10-13 As shown, the AKP enzyme activity of the four bacteria treated with the antimicrobial peptide PVQ9 increased, and the AKP enzyme activity increased in a dose-dependent manner.

[0074] Example 6: Effect of antimicrobial peptide PVQ9 on bacterial cell membrane permeability

[0075] Propidium iodide (PI) staining was used to analyze the effect of the antimicrobial peptide PVQ9 on bacterial cell membrane permeability. Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella giardi were inoculated into LB broth and cultured at 37°C and 200 rpm until they reached the logarithmic growth phase. A certain amount of bacterial culture in the logarithmic growth phase was collected, centrifuged, and the supernatant was discarded. The collected bacterial cells were washed three times with 0.01M pH 7.2 phosphate buffer, and the bacterial concentration was adjusted to 10. 5-6 CFU / mL. Antimicrobial peptide PVQ9 was dissolved in phosphate buffer to concentrations of 1 / 2×MBC, 1×MBC, and 2×MBC. The blank control group was replaced with phosphate buffer. The mixture was incubated at 37°C with bacteria in equal volumes for 2 hours. After incubation, 100 μL was centrifuged, the supernatant was discarded, and 100 μL of PI dye was added. The mixture was vortexed at 25°C and incubated at 4°C in the dark for 15 minutes. After staining, the sample was washed twice with 0.1M PBS and resuspended in 100 μL. The fluorescence spectrum of the sample in the excitation wavelength range of 535 nm and the emission wavelength range of 550–750 nm was measured using a multi-functional microplate reader. PI is a nucleic acid dye with the strongest fluorescence absorption at an excitation wavelength of 535 nm and an emission wavelength of 615 nm. It cannot cross the normal cell membrane, but when the cell membrane is damaged or ruptured, PI can enter the cell membrane and bind to DNA, displaying red fluorescence. The degree of cell damage can be determined based on the fluorescence intensity. The binding of PI to bacterial genomic DNA treated with different concentrations of antimicrobial peptides is as follows: Figures 14-17As shown in the figure, the fluorescence intensity of the four types of bacteria treated with different concentrations of antimicrobial peptide PVQ9 was higher than that of the blank control group, indicating that PVQ9 treatment damaged the bacterial cell membrane and increased its permeability. The fluorescence intensity of the sample treated with 2×MBC PVQ9 was greater than that of the sample treated with 1×MBC PVQ9, indicating that high doses of PVQ9 increased bacterial cell membrane permeability, leading to more PI entering the cell, binding to DNA, and emitting fluorescence.

[0076] Example 7: Effect of antimicrobial peptide PVQ9 on bacterial cell membrane permeability (protein leakage)

[0077] Bacterial cell membrane integrity is assessed by measuring the leakage of intracellular proteins. Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella gibrini were inoculated into LB broth and cultured at 37°C and 200 rpm until they reached the logarithmic growth phase. A certain amount of bacterial culture in the logarithmic phase was collected, centrifuged, and the supernatant was discarded. The collected bacterial cells were washed three times with 0.01M pH 7.2 phosphate buffer, and the bacterial concentration was adjusted to 10. 6 CFU / mL. Antimicrobial peptides were dissolved in phosphate buffer to concentrations of 1 / 2×MBC, 1×MBC, and 2×MBC. The blank control group was replaced with phosphate buffer. Equal volumes of the solutions were mixed with bacteria and incubated at 37°C using a multi-functional microplate reader. OD values ​​were measured at different time points. 280 The absorbance was measured. The results are as follows: Figures 18-21 As shown, the protein content in the bacterial culture of the four strains in the blank control group was low, while the protein permeation in the bacterial culture treated with antimicrobial peptide PVQ9 was significantly higher than that in the control group, and the protein permeation in the bacterial culture increased with the increase of antimicrobial peptide PVQ9 concentration.

[0078] Example 8: Interaction between antimicrobial peptide PVQ9 and bacterial DNA

[0079] The interaction between the antimicrobial peptide PVQ9 and the genomic DNA of *Staphylococcus aureus*, *Bacillus cereus*, *Staphylococcus squirrelii*, and *Kurantella giardi* was investigated using the DNA gel retardation method. Bacteria were cultured in 50 mL of nutrient broth (NB) at 37 °C for 12 h, and bacterial genomic DNA was extracted using a bacterial genomic DNA extraction kit. The optical density ratio (OD) at 260 and 280 nm was compared with that at 280 nm. 260 / OD 280The purity of the extracted genomic DNA was evaluated using a concentration ≥1.90. Next, 10 μL of Staphylococcus aureus DNA (68 ng / μL), Bacillus cereus DNA (161 ng / μL), Staphylococcus aureus DNA (114 ng / μL), and Curtaella giardi DNA (79 ng / μL) were mixed with a continuous amount of the antimicrobial peptide PVQ9 at 25°C for 90 min. The mixture was then electrophoresed on a 0.8% agarose gel. Gel retardation was observed under UV irradiation using a GelDocXR gel imaging system (Bio-Rad, USA). Figures 22-25 As shown, different concentrations of the antimicrobial peptide PVQ9 did not cause significant migration of the bacterial DNA bands in *Staphylococcus aureus*, *Bacillus cereus*, *Staphylococcus squirrelii*, and *Cuora gibrini*. In band 6-1, the brightness of the DNA band decreased significantly with increasing PVQ9 concentration, indicating that PVQ9 has a degrading effect on the DNA of *Staphylococcus aureus*, *Bacillus cereus*, *Staphylococcus squirrelii*, and *Cuora gibrini*.

[0080] Example 9: Fluorescence spectroscopy experiment on the competitive binding of antimicrobial peptide PVQ9 to DNA by EB

[0081] Fluorescence spectroscopy experiments were conducted to analyze the competitive binding mechanism of antimicrobial peptide PVQ9 to bacterial genomic DNA. Genomic DNA from *Staphylococcus aureus*, *Bacillus cereus*, *Staphylococcus squirrelii*, and *Cootrella gigantea* was diluted to 50 μg / mL using TE buffer. The reaction was performed in 96-well plates. First, 5 μL of DNA solution and 10 μL of 100 μg / mL EB solution were added to each well, mixed, and incubated at 37°C in the dark for 10 min. Next, 50 μL of peptide solutions of different concentrations were added, with 50 μL of sterile distilled water used as a blank control group. After mixing, the plates were incubated at 37°C in the dark for 30 min. After incubation, the fluorescence spectra of the samples were measured using a multi-mode microplate reader in the excitation wavelength range of 535 nm and the emission wavelength range of 550–750 nm. In aqueous solution, EB exhibits weak fluorescence, but its fluorescence intensity increases significantly when it binds to double-stranded DNA via intercalation with high affinity. If a substance in the EB-DNA complex system that interacts similarly with DNA competes with EB for binding to the DNA, the fluorescence intensity of the system decreases, indicating that the competitor binds to DNA through intercalation, similar to EB. Therefore, by measuring the changes in the fluorescence spectrum of the DNA-EB complex system interacting with the competitor, it can be determined whether the competitor also binds to DNA via intercalation, similar to EB. Figures 26-29It can be seen that as the concentration of antimicrobial peptide PVQ9 increases, the fluorescence intensity of the EB-DNA complex decreases, indicating that the antimicrobial peptide PVQ9 intercalates with Bacillus cereus DNA, competing with EB that was previously bound to the DNA base pairs, and replacing EB to bind to the DNA in an intercalating manner, thus reducing the fluorescence intensity of the entire system.

[0082] Example 10: Application of antimicrobial peptide PVQ9 in tofu

[0083] After being sterilized in an autoclave at 121℃ for 15 minutes, the packaged tofu was cooled in a clean bench and cut into several small pieces of similar size, each weighing approximately 30.0g. These pieces were randomly divided into four groups and treated as follows: one group received no treatment; one group was inoculated with diluted *Cootrophus giganteus* culture to achieve a colony count of 40 CFU / g; one group was inoculated with PVQ9 containing 1×MBC and then inoculated with an equal amount of *Cootrophus giganteus*; and one group was inoculated with PVQ9 containing 2×MBC and then inoculated with an equal amount of *Cootrophus giganteus*. Sensory evaluation was performed, and the total bacterial count, amino acid nitrogen, and pH were measured. The results of tofu storage for 48 hours are as follows: Figure 30 As shown in the figure. The initial state of the tofu samples was milky white, moist, elastic, without mucus, and odor. The tofu samples in the blank control group showed little overall change after 48 hours of storage. The tofu samples inoculated only with *Cootrella gigantea* showed a slight odor starting after 12 hours of storage; after 48 hours, the overall color turned dark yellow, the texture softened, more mucus was produced, and a strong rancid odor appeared. The tofu treated with the antimicrobial peptide PVQ9 at a concentration of 1×MBC showed a slight odor starting after 36 hours of storage; after 48 hours, the overall color turned yellow, the texture softened, a small amount of mucus was produced, and a rancid odor appeared, but the overall degree of spoilage was less than the group treated only with bacterial re-inoculation. The tofu treated with the antimicrobial peptide PVQ9 at a concentration of 2×MBC only showed a slight odor after 48 hours of storage; the overall color was slightly yellow, the texture was slightly less elastic, and no mucus was produced. The effect of adding the antimicrobial peptide PVQ9 on the total number of *Cootrella gigantea* colonies during tofu storage is shown in the figure. Figure 31 As shown in the figure, the addition of antimicrobial peptides effectively inhibited bacterial growth. After 48 hours of storage, the total bacterial count in tofu treated with the antimicrobial peptide PVQ9 at a concentration of 1×MBC was significantly lower than that in the untreated group, and the higher the concentration of antimicrobial peptide PVQ9, the lower the total bacterial count. The effect of adding antimicrobial peptide PVQ9 on the soluble amino acid nitrogen during tofu storage is shown in the figure. Figure 32As shown in the figure, amino acid nitrogen content is an important indicator of the degree of protein hydrolysis. Bacteria produce proteases during their growth and metabolism, which hydrolyze the proteins in tofu. Therefore, a higher amino acid nitrogen content indicates more severe protein hydrolysis and more vigorous bacterial growth and metabolism. The figure shows that the amino acid nitrogen content of the tofu samples in the blank control group did not change significantly after 48 hours of storage. However, the amino acid nitrogen content of the tofu samples treated with only *Cootrella gigantea* increased to 0.27 g / 100g after 48 hours of storage. In contrast, the amino acid nitrogen content of the tofu treated with antimicrobial peptide PVQ9 at concentrations of 1×MBC and 2×MBC were 0.208 g / 100g and 0.176 g / 100g, respectively, both lower than the samples treated with only bacterial re-inoculation. This result indicates that antimicrobial peptide PVQ9 can inhibit bacterial growth and metabolism, reducing the degree of protein hydrolysis in tofu. The effect of adding antimicrobial peptide PVQ9 on pH during tofu storage is shown in the figure. Figure 33 As shown, *Cootrella gigantea* has a relatively small impact on the pH value of tofu, remaining essentially stable. Sensory evaluation, changes in total bacterial count, and changes in soluble amino acid nitrogen indicate that due to the large-scale proliferation of *Cootrella gigantea*, the higher the degree of protein hydrolysis in tofu, the faster the tofu spoils. However, the addition of the antimicrobial peptide PVQ9 can reduce the number of viable bacteria, decrease the degree of protein hydrolysis, and slow down the spoilage rate of tofu. Furthermore, the effect of PVQ9 on the antimicrobial peptide is concentration-dependent. These results suggest that the antimicrobial peptide PVQ9 can be used as a novel food preservative for tofu preservation.

[0084] In summary, this invention provides a novel antimicrobial peptide, PVQ9. The minimum bactericidal concentrations (MBCs) of this peptide against Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Curtaella giardi are 62.5 μg / mL, 62.5 μg / mL, 31.25 μg / mL, and 31.25 μg / mL, respectively, and all four bacteria are killed within 2 hours, indicating that antimicrobial peptide PVQ9 has a strong inhibitory effect on these four bacteria. The antimicrobial peptide PVQ9 of this invention first disrupts the bacterial cell wall, penetrates the bacterial cell membrane, and alters the cell membrane permeability. Then, it binds to the bacterial genomic DNA, inhibiting bacterial DNA synthesis, thereby leading to bacterial death.

[0085] While specific embodiments of the present invention have been described above, those skilled in the art should understand that the specific embodiments described are merely illustrative and not intended to limit the scope of the present invention. Equivalent modifications and variations made by those skilled in the art in accordance with the spirit of the present invention should be covered within the scope of protection of the claims of the present invention.

Claims

1. The application of the antimicrobial peptide PVQ9 of Litopenaeus vannamei β-actin, with the amino acid sequence shown in SEQ ID NO: 1, in the preparation of antimicrobial drugs, characterized in that: The antibacterial drug is used to inhibit and / or kill one or more of Staphylococcus aureus, Bacillus cereus, Staphylococcus aureus, and Cuttlebacter giardi.

Citation Information

Patent Citations

  • Application of Chinese angelica polypeptide with effects of resisting oxidization and delaying ageing in preparation of food

    CN104522683A

  • Character polypeptide for identifying cinobufagin preparation or toad skin as well as content determination method and application thereof

    CN115184480A

  • Viral peptides

    US20160367659A1